Advances in Clinical and Experimental Medicine
2017, vol. 26, nr 8, November, p. 1171–1178
Publication type: original article
Mesenchymal stem cell therapy of hepatocellular carcinoma in rats: Detection of cell homing and tumor mass by magnetic resonance imaging using iron oxide nanoparticles
1 Department of Medical Laboratory, College of Health Sciences, King Abdulaziz University, Jeddah, Saudi Arabia
2 Department of Clinical Biochemistry, College of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
3 Stem Cell Unit, King Fahd Center for Medical Research, King Abdulaziz University, Jeddah, Saudi Arabia
4 Department of Clinical Biochemistry, Faculty of Medicine, Rabigh, King Abdulaziz University, Jeddah, Saudi Arabia
5 Department of Medical Biochemistry, Faculty of Medicine, Cairo University, Egypt
6 Department of Radiology, King Abdul Aziz University Hospital, King Abdulaziz University, Jeddah, Saudi Arabia
7 Department of Pediatrics, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
8 Department of Pathology, Faculty of Medicine, Cairo University, Egypt
9 Department of Pathology, Rabigh Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
Background. Bone marrow-derived mesenchymal stem cells (MSCs) are reported to improve hepatic fibrosis, and may impact the signaling mechanisms leading to the induction of hepatocellular carcinoma (HCC) in animal models of liver cirrhosis.
Objectives. The aim of this study was to clarify and explain the therapeutic role played by MSCs in hepatic cirrhosis and HCC by tracking them using nanoparticles.
Material and Methods. Liver cirrhosis and HCC were established in rats with the use of carbon tetrachloride and diethylnitrosamine injection. Magnetic resonance imaging (MRI) was used to track nanoparticlelabeled MSCs in the intact animal following injection and to monitor the changes in the hepatic parenchyma.
Results. Labeling of MSCs with iron oxide nanoparticles did not adversely affect their viability and proliferation. MRI indicated a significant reduction in tumor mass in the labeled MSCs group compared to the control group. Histopathologic examination of the liver, following MSCs treatment, showed an apparently normal looking liver with no evidence of neoplastic cellular changes. The biochemical results support these findings.
Conclusion. This work documents that MSCs could be labeled with nanoparticles and traced in normal and cirrhotic liver and in liver with HCC in animals using MRI. MRI monitors the homing and localization of MSCs in the liver. MSCs infusion in animal models of cirrhosis and carcinoma may prove to be useful in limiting the cirrhotic process. Also, it may have a possible therapeutic potential on the carcinogenic process.
liver cirrhosis, nanoparticles, stem cells, hepatocellular carcinoma
- Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene. 2010;29:4989–5005.
- Seeff LB, Hoofnagle JH. Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity. Oncogene. 2006;25:3771–3777.
- Shah K. Mesenchymal stem cells engineered for cancer therapy. Adv Drug Deliv Rev. 2012;64:739–748
- Qiao L, Xu Z, Zhao T, et al. Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model. Cell Res. 2008;18:500–507.
- Long X, Matsumoto R, Yang P, Uemura T. Effect of human mesenchymal stem cells on the growth of HepG2 and Hela cells. Cell Struct Funct. 2013;38(1):109–121.
- Livraghi T, Meloni F, Frosi A, et al. Treatment with stem cell differentiation stage factors of intermediate-advanced hepatocellular carcinoma: An open randomized clinical trial. Oncol Res. 2005;15:399–408.
- Ringden O, Le Blanc K. Allogeneic hematopoietic stem cell transplantation: State of the art and new perspectives. APMIS. 2005;113:813–830.
- Lysy PA, Campard D, Smets F, Najimi M, Sokal EM. Stem cells for liver tissue repair: Current knowledge and perspectives. World J Gastroenterol. 2008;14:864–875.
- Kim TH, Kim JK, Shim W, Kim SY, Park TJ, Jung JY. Tracking of transplanted mesenchymal stem cells labeled with fluorescent magnetic nanoparticle in liver cirrhosis rat model with 3-T MRI. Magn Reson Imaging. 2010;28:1004–1013.
- Abdelaziz MT, Atta HM, Mahfouz H, et al. Therapeutic potential of bone marrow-derived mesenchymal stem cellson experimental liver fibrosis. Clin Biochem. 2007;40:893–899.
- Yanai A, Häfeli UO, Metcalfe AL, et al. Focused magnetic stem cell targeting to the retina using superparamagnetic iron oxide nanoparticles. Cell Transplant. 2012;21:1137–1148.
- Babic M, Horak D, Trchova M, et al. Poly (L-lysine)-modified iron oxide nanoparticles for stem cell labeling. Bioconjug Chem. 2008;19:740–750.
- Abdel Aziz MT, El Asmar MF, Atta HM, et al. Efficacy of mesenchymal stem cells in suppression of hepatocarcinorigenesis in rats: Possible role of Wnt signaling. J Exp Clin Cancer Res. 2011;30(1):49.
- Wang L, Deng J, Wang J, et al. Superparamagnetic iron oxide does not affect the viability and function of adipose-derived stem cells, and superparamagnetic iron oxide-enhanced magnetic resonance imaging identifies viable cells. Magn Reson Imaging. 2009;27:108–119.
- Bayo J, Fiore E, Aquino JB, et al. Increased migration of human mesenchymal stromal cells by autocrine motility factor (AMF) resulted in enhanced recruitment towards hepatocellular carcinoma. PLoS One. 2014;9:e95171.
- Bitar R, Leung G, Perng R, et al. MR pulse sequences: What every radiologist wants to know but is afraid to ask. Radiographics. 2006;26:513–537.
- Papakonstantinou O, Kostaridou S, Maris T, et al. Quantification of liver iron overload by T2 quantitative magnetic resonance imaging in thalassemia: Impact of chronic hepatitis C on measurements. J Pediatr Hematol Oncol. 1999;21:142–148.
- Yu NC, Chaudhari V, Raman SS, et al. CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clin Gastroenterol Hepatol. 2011;9:161–167.
- Zhao S, Wang Y, Gao C, et al. Superparamagnetic iron oxide magnetic nanomaterial-labeled bone marrow mesenchymal stem cells for rat liver repair following hepatectomy. J Surg Res. 2014;191:290–301.
- Bos C, Delmas Y, Desmouliere A, et al. In vivo MR imaging of intravascularly injected magnetically labeled mesenchymal stem cells in rat kidney and liver. Radiology. 2004;233:781–789.
- Schmidt VA, Chiariello CS, Capilla E, Miller F, Bahou WF. Development of hepatocellular carcinoma in Iqgap2-deficient mice is IQGAP1 dependent. Mol Cell Biol. 2008;28:1489–1502.